SEC Form	n 4																
FORM 4 UN				NITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL		
Section 16. Form 4 or Form 5 obligations may continue. See					ed purs	NT OF CHANGES IN BENEFICIAL OWNE d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940								COMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
1. Name and Address of Reporting Person [*] Peterson Amy C.									er or Trading eutics, Inc			ck all applic Director	able)	Person(s) to Is 10% C Other below	wner (specify		
(Last)(First)(Middle)C/O CYTOMX THERAPEUTICS, INC.151 OYSTER POINT BLVD., STE. 400					3. Date of Earliest Transaction (Month/Day/Year) 10/24/2021								EVP, Chief Development Officer				
(Street) SOUTH SAN FRANCISCO CA 94080					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							dividual or Joint/Group Filing (Check Applicable) K Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(Sta		Zip)										<u> </u>				
Table I - Non-Deriv 1. Title of Security (Instr. 3) 2. Transa Date (Month/L)				action	ction 2A. Deemed Execution Date,			3. Transaction Code (Instr	Transaction Code (Instr. 5) 8)		d (A) or	5. Amount of		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
		Т	able II -	Deriva (e.g., r	tive S	Secu calls	rities /	Acquants	uired, Disp , options,	osed of,	or Bene	ficially rities)	<u> </u>				
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Exe ecurity or Exercise (Month/Day/Year) if a		3A. Deem Execution if any	A. Deemed Execution Date,		action Instr.	5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownersh Form: Direct (D) or Indirec (I) (Instr.	t (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$5.34	10/24/2021			A		50,000		(1)	10/23/2031	Common Stock	50,000	\$0.00	50,000	D		
Performance Stock Units (PSUs)	(2)	10/24/2021			A		40,000		(2)	(2)	Common Stock	40,000	\$0.00	40,000	D		

Explanation of Responses:

1. 1/48th of the shares subject to the option vest on each monthly anniversary measured from October 24, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

2. Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone within 1 year from grant date and 50% of the PSUs vest upon achievement of a certain performance-based milestone within 2 years from grant date.

<u>/s/ Lloyd Rowland, as Attorney-</u> in Fact for Amy C. Poterson	10/20/2021
in-Fact for Amy C. Peterson	10/20/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.